Yuhao Xie

Dr. Yuhao Xie

Department of Pharmaceutical Sciences, St. John's University, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2022 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
ZLZi-Ning Lei
Zi-Ning Lei
QTQiu-Xu Teng
Qiu-Xu Teng
QTQin Tian
Qin Tian
WCWei Chen
Wei Chen
Yuhao XieYuhao Xie
Yuhao Xie
YHYulong He
Yulong He
Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death. Despite tremendous progress in diagnosis and therapeutic strategies and significant improvements in patient survival, the low malignancy stage is relatively asymptomatic and many GC cases are diagnosed at advanced stages, which leads to unsatisfactory prognosis and high recurrence rates. With the recent advances in genome analysis, biomarkers have been identified that have clinical importance for GC diagnosis, treatment, and prognosis. Modern molecular classifications have uncovered the vital roles that signaling pathways, including EGFR/HER2, p53, PI3K, immune checkpoint pathways, and cell adhesion signaling molecules, play in GC tumorigenesis, progression, metastasis, and therapeutic responsiveness. These biomarkers and molecular classifications open the way for more precise diagnoses and treatments for GC patients. Nevertheless, the relative significance, temporal activation, interaction with GC risk factors, and crosstalk between these signaling pathways in GC are not well understood. Here, we review the regulatory roles of signaling pathways in GC potential biomarkers, and therapeutic targets with an emphasis on recent discoveries. Current therapies, including signaling-based and immunotherapies exploited in the past decade, and the development of treatment for GC, particularly the challenges in developing precision medications, are discussed. These advances provide a direction for the integration of clinical, molecular, and genomic profiles to improve GC diagnosis and treatments.

17 January 2023 in Drug Resistance Updates
Verified
Journal Article
Open access
JJJuan Jin
Juan Jin
Yuhao XieYuhao Xie
Yuhao Xie
JZJin-Shi Zhang
Jin-Shi Zhang
JWJing-Quan Wang
Jing-Quan Wang
SDShi-Jie Dai
Shi-Jie Dai
QHQiang He
Qiang He
Currently, renal cell carcinoma (RCC) is the most prevalent type of kidney cancer. Targeted therapy has replaced radiation therapy and chemotherapy as the main treatment option for RCC due to the lack of significant efficacy with these conventional therapeutic regimens. Sunitinib, a drug used to treat gastrointestinal tumors and renal cell carcinoma, inhibits the tyrosine kinase activity of a number of receptor tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), c-Kit, rearranged during transfection (RET) and fms-related receptor tyrosine kinase 3 (Flt3). Although sunitinib has been shown to be efficacious in the treatment of patients with advanced RCC, a significant number of patients have primary resistance to sunitinib or acquired drug resistance within the 6-15 months of therapy. Thus, in order to develop more efficacious and long-lasting treatment strategies for patients with advanced RCC, it will be crucial to ascertain how to overcome sunitinib resistance that is produced by various drug resistance mechanisms. In this review, we discuss: 1) molecular mechanisms of sunitinib resistance; 2) strategies to overcome sunitinib resistance and 3) potential predictive biomarkers of sunitinib resistance.

17 November 2022 in Drug Resistance Updates
Verified
Journal Article
Closed access
AUAditya Upadhayay
Aditya Upadhayay
JLJingjing Ling
Jingjing Ling
DPDharm Pal
Dharm Pal
Yuhao XieYuhao Xie
Yuhao Xie
FPFeng-Feng Ping
Feng-Feng Ping
AKAwanish Kumar
Awanish Kumar

13 June 2024 in Cancer Letters
Verified
Journal Article
Closed access
LCLu-Qi Cao
Lu-Qi Cao
Yuhao XieYuhao Xie
Yuhao Xie
JFJoshua S. Fleishman
Joshua S. Fleishman
XLXuan Liu
Xuan Liu
Zhe-Sheng ChenZhe-Sheng Chen
Zhe-Sheng Chen

1 September 2024 in Journal of Translational Internal Medicine
Verified
Journal Article
Open access
PDF file
MKMiao Ke
Miao Ke
HZHuimin Zhu
Huimin Zhu
YLYu Lin
Yu Lin
YZYing Zhang
Ying Zhang
TTTao Tang
Tao Tang
YSYuan Shen
Yuan Shen
Background and Objectives: Actin-related protein 2/3 complex subunit 1B (ARPC1B) is an essential subunit of the actin-related protein 2/3 (Arp2/3) complex. While there have been numerous research reports on Arp2/3 in relation to tumors, there needs to be more research on ARPC1B and its role in tumors, particularly at the pan-cancer level. Methods: Utilizing data from the cancer genome atlas (TCGA) and genotype-tissue expression (GTEx) databases, we analyzed ARPC1B expression differences in normal, tumor, and adjacent tissues, investigating its correlation with prognosis and clinical stages in various cancers. We conducted gene enrichment analysis and explored ARPC1B’s connection to the tumor immune microenvironment and its impact on anti-tumor drug resistance. In addition, in vivo and in vitro experiments have also been carried out to find the mechanism of ARPC1B on ovarian cancer (OV) proliferation and invasion. Results: ARPC1B was highly expressed in 33 tumor types, suggesting its role as a tumor-promoting factor. Its expression correlated with poor prognosis and served as a clinical staging marker in over 10 tumor types. ARPC1B is implicated in various biological processes and signaling pathways, uniquely associated with tumor immunity, indicating immunosuppressive conditions in high-expression cases. High ARPC1B expression was linked to resistance to six anti-tumor drugs. Further experiments showed that ARPC1B can affect the proliferation, apoptosis, migration, and invasion of OV cells through the AKT/PI3K/mTOR pathway. Conclusion: ARPC1B is a biomarker for immune suppression, prognosis, clinical staging, and drug resistance, providing new insights for cancer therapeutics.

24 January 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
LCLu-Qi Cao
Lu-Qi Cao
HSHaidong Sun
Haidong Sun
Yuhao XieYuhao Xie
Yuhao Xie
HPHarsh Patel
Harsh Patel
LBLetao Bo
Letao Bo
Zhe-Sheng ChenZhe-Sheng Chen
Zhe-Sheng Chen
Breast cancer, a complex and varied disease, has four distinct subtypes based on estrogen receptor and human epidermal growth factor receptor 2 (HER2) levels, among which a significant subtype known as HR+/HER2-breast cancer that has spurred numerous research. The prevalence of breast cancer and breast cancer-related death are the most serious threats to women’s health worldwide. Current progress in treatment strategies for HR+/HER2-breast cancer encompasses targeted therapy, endocrine therapy, genomic immunotherapy, and supplementing traditional methods like surgical resection and radiotherapy. This review article summarizes the current epidemiology of HR+/HER2-breast cancer, introduces the classification of HR+/HER2-breast cancer and the commonly used treatment methods. The mechanisms of action of various drugs, including targeted therapy drugs and endocrine hormone therapy drugs, and their potential synergistic effects are deeply discussed. In addition, clinical trials of these drugs that have been completed or are still in progress are included.